SIRT1 and metabolic dysfunction-associated steatohepatitis: Based on the pivotal role of the AMPK/Sirt1/eNOS network in hepatic metabolism and the promising results of this animal study, the Sild-Met-Leu combination provides a new therapeutic approach to treat NAFLD and NASH.